Santhera Pharmaceuticals Holding AG SANN-Financial and Strategic SWOT Analysis Review

Santhera Pharmaceuticals Holding AG SANN-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH82467FSA
  • |
  • Pages: 44
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Santhera Pharmaceuticals Holding AG (SANN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Santhera Pharmaceuticals Holding AG (Santhera) is a pharmaceutical company that develops and commercializes novel pharmaceutical products indicated for patients with rare mitochondrial diseases. It specifically focuses in the area of neuromuscular and neuro-ophthalmological conditions. The company's lead product candidate, Raxone (idebenone), is developed for the treatment of Leber's hereditary optic neuropathy. Raxone is also investigated for other diseases such as Duchenne Muscular Dystrophy and Primary Progressive Multiple Sclerosis. Santhera's pipeline also includes other compound namely, omigapil for congenital muscular dystrophies. It operates along with its subsidiaries located in Switzerland, Germany, Canada, Finland and the US. Santhera is headquartered in Liestal, Switzerland.

Santhera Pharmaceuticals Holding AG Key Recent Developments

Apr 12, 2016: Santhera Reports Increase in Product Sales, Positive Net Result for 2015 and Progress in All Programs

Apr 14, 2015: Santhera Reports 2014 Financial Results and Significant Progress in All Programs

Jan 30, 2015: Santhera Extends Executive Management and Appoints Chief Commercial Officer

Jan 23, 2015: Santhera reports preliminary key financial figures for 2014

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Section 1-About the Company 6

Santhera Pharmaceuticals Holding AG-Key Facts 6

Santhera Pharmaceuticals Holding AG-Key Employees 7

Santhera Pharmaceuticals Holding AG-Key Employee Biographies 8

Santhera Pharmaceuticals Holding AG-Major Products and Services 9

Santhera Pharmaceuticals Holding AG-Pharmaceutical Pipeline Products Data 10

Santhera Pharmaceuticals Holding AG, Pipeline Products by Therapy Area 10

Santhera Pharmaceuticals Holding AG, Pipeline Products by Development Phase 11

Santhera Pharmaceuticals Holding AG-History 13

Santhera Pharmaceuticals Holding AG-Company Statement 16

Santhera Pharmaceuticals Holding AG-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Section 2-Company Analysis 19

Santhera Pharmaceuticals Holding AG-Business Description 19

Santhera Pharmaceuticals Holding AG-Corporate Strategy 20

Santhera Pharmaceuticals Holding AG-SWOT Analysis 21

SWOT Analysis-Overview 21

Santhera Pharmaceuticals Holding AG-Strengths 21

Strength-Strong Research and Development Capabilities 21

Strength-Lead Product: Roxane/Catena 21

Strength-Intellectual Property 21

Santhera Pharmaceuticals Holding AG-Weaknesses 22

Weakness-Cost Structure 22

Santhera Pharmaceuticals Holding AG-Opportunities 23

Opportunity-Growth Potential: Orphan Drugs 23

Opportunity-Strategic Initiatives 23

Opportunity-Market Potential: DMD 23

Santhera Pharmaceuticals Holding AG-Threats 24

Threat-Competitive Pressures 24

Threat-Uncertain R&D Outcomes 24

Threat-Lack of Manufacturing Facilities 24

Santhera Pharmaceuticals Holding AG-Key Competitors 25

Section 3-Company Financial Ratios 26

Financial Ratios-Capital Market Ratios 26

Financial Ratios-Annual Ratios 27

Performance Chart 28

Financial Performance 28

Financial Ratios-Interim Ratios 29

Financial Ratios-Ratio Charts 30

Section 4-Company's Lifesciences Financial Deals and Alliances 31

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 31

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 32

Santhera Pharmaceuticals Holding AG, Recent Deals Summary 33

Section 5-Company's Recent Developments 34

Apr 12, 2016: Santhera Reports Increase in Product Sales, Positive Net Result for 2015 and Progress in All Programs 34

Apr 14, 2015: Santhera Reports 2014 Financial Results and Significant Progress in All Programs 36

Jan 30, 2015: Santhera Extends Executive Management and Appoints Chief Commercial Officer 38

Jan 23, 2015: Santhera reports preliminary key financial figures for 2014 39

Section 6-Appendix 40

Methodology 40

Ratio Definitions 40

About GlobalData 44

Contact Us 44

Disclaimer 44

List of Figures

Santhera Pharmaceuticals Holding AG, Pipeline Products by Therapy Area 10

Santhera Pharmaceuticals Holding AG, Pipeline Products by Development Phase 11

Santhera Pharmaceuticals Holding AG, Performance Chart (2011-2015) 28

Santhera Pharmaceuticals Holding AG, Ratio Charts 30

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 31

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 32

List of Tables

Santhera Pharmaceuticals Holding AG, Key Facts 6

Santhera Pharmaceuticals Holding AG, Key Employees 7

Santhera Pharmaceuticals Holding AG, Key Employee Biographies 8

Santhera Pharmaceuticals Holding AG, Major Products and Services 9

Santhera Pharmaceuticals Holding AG, Number of Pipeline Products by Therapy Area 10

Santhera Pharmaceuticals Holding AG, Number of Pipeline Products by Development Stage 11

Santhera Pharmaceuticals Holding AG, Pipeline Products By Therapy Area and Development Phase 12

Santhera Pharmaceuticals Holding AG, History 13

Santhera Pharmaceuticals Holding AG, Subsidiaries 18

Santhera Pharmaceuticals Holding AG, Key Competitors 25

Santhera Pharmaceuticals Holding AG, Ratios based on current share price 26

Santhera Pharmaceuticals Holding AG, Annual Ratios 27

Santhera Pharmaceuticals Holding AG, Interim Ratios 29

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 31

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 32

Santhera Pharmaceuticals Holding AG, Recent Deals Summary 33

Currency Codes 40

Capital Market Ratios 40

Equity Ratios 41

Profitability Ratios 41

Cost Ratios 42

Liquidity Ratios 42

Leverage Ratios 43

Efficiency Ratios 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Sarepta Therapeutics, Inc.

NicOx S.A.

GTx, Inc.

Capricor Therapeutics, Inc.

Applied Genetic Technologies Corporation

Santhera Pharmaceuticals Holding AG, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license

Single User License
USD 125 INR 8131
Site License
USD 250 INR 16263
Corporate User License
USD 375 INR 24394

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com